Houston-based biotech company Kiromic BioPharma has partnered with Beverly Hills Cancer Center (BHCC) to conduct a groundbreaking lung cancer study. BHCC will be the first of up to four prestigious clinical sites to evaluate Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, named Deltacel™ (KB-GDT-01), in patients with non-small cell lung cancer (NSCLC). The collaboration between Kiromic BioPharma and BHCC reflects their shared commitment to advancing cancer treatment through innovative therapies. NSCLC is the most common type of lung cancer, accounting for 80% to 85% of cases.
BHCC is well-equipped for the study, with a radiation oncology center, infusion center, diagnostic imaging center, and diagnostic laboratory. The center has a history of conducting clinical trials in various cancer types. Dr. Afshin Eli Gabayan, Medical Director and Principal Investigator at BHCC, expressed excitement about the collaboration, as it allows patients to access pioneering therapies and offers renewed hope in their battle against cancer.
This partnership marks a momentous first step in the development of this important treatment. BHCC was chosen as the initial clinical site based on its proven track record in clinical research and exceptional patient care. However, Kiromic BioPharma is actively engaging with other prestigious clinical trial sites to expand the reach and impact of the study, with a total of up to four sites expected to participate. Updates on the progress of the Deltacel-01 clinical study, including subsequent site activations, will be provided as the trial progresses.
Lung cancer is the leading cause of cancer-related deaths in the U.S., responsible for approximately one in five cancer deaths. Kiromic BioPharma aims to contribute to science and improve the lives of cancer patients worldwide through their innovative Deltacel™ therapy. The company utilizes its proprietary DIAMOND® artificial intelligence and data mining platform to develop and commercialize cell therapies in the field of immuno-oncology. Kiromic’s approach leverages Gamma Delta T-cells’ natural potency, focusing on solid tumor targeting. They believe that combining data science with target identification will significantly reduce the time and cost required to develop live drugs.
Kiromic maintains offices in Houston, Texas, and is dedicated to advancing the fight against cancer through cutting-edge therapeutic approaches. As the collaboration with BHCC commences the groundbreaking clinical trial, the future holds the promise of improved treatment options and outcomes for lung cancer patients.
Frequently Asked Questions (FAQs) Related to the Above News
What is the purpose of the lung cancer study conducted by Kiromic BioPharma and Beverly Hills Cancer Center?
The purpose of the study is to evaluate Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell therapy, called Deltacel™ (KB-GDT-01), in patients with non-small cell lung cancer (NSCLC) at Beverly Hills Cancer Center (BHCC).
How many clinical sites are expected to participate in the study?
Up to four prestigious clinical sites, including BHCC, are expected to participate in the study.
Why was BHCC chosen as the initial clinical site for the study?
BHCC was chosen based on its proven track record in clinical research and exceptional patient care.
What resources does BHCC have that make it well-equipped for the study?
BHCC has a radiation oncology center, infusion center, diagnostic imaging center, and diagnostic laboratory, which provide the necessary resources for conducting the study.
What is the significance of the study in the development of the treatment?
This partnership marks an important first step in the development of Kiromic's Deltacel™ therapy for lung cancer. It allows for the evaluation of the therapy in a clinical setting, bringing patients closer to potentially accessing innovative treatments.
What is the most common type of lung cancer?
Non-small cell lung cancer (NSCLC) is the most common type, accounting for 80% to 85% of cases.
How does Kiromic BioPharma aim to contribute to cancer treatment?
Kiromic BioPharma aims to contribute to cancer treatment by utilizing their proprietary DIAMOND® artificial intelligence and data mining platform to develop and commercialize cell therapies in the field of immuno-oncology, with a focus on solid tumor targeting using Gamma Delta T-cells.
What is the leading cause of cancer-related deaths in the U.S.?
Lung cancer is the leading cause of cancer-related deaths in the U.S., responsible for approximately one in five cancer deaths.
What is Kiromic BioPharma's approach to developing live drugs?
Kiromic BioPharma combines data science with target identification to develop live drugs. They believe that this approach will significantly reduce the time and cost required for drug development.
Where is Kiromic BioPharma headquartered?
Kiromic BioPharma is headquartered in Houston, Texas.
What are the expected outcomes of the groundbreaking clinical trial?
The collaboration between Kiromic BioPharma and BHCC holds the promise of improved treatment options and outcomes for lung cancer patients.
Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.
